Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for Vascular Inflammation in CAD with or without TET2 Mutations
NCT06691217Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2026
- Primary completion
- Jan 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary artery disease (CAD) and vasculitis comparing Placebo: Control with Treatment: Canakinumab (2 arms). Primary endpoint: Change in perivascular fat attenuation index at 48 weeks. Started Mar 2026; status: recruiting.
02
Drugs
canakinumab
03
Conditions
coronary artery disease (CAD)vasculitis
Beyond the preview
Go deeper on NCT06691217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691217.